NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio With Three New Antigens Via Series Of Rights Acquisitions
6/10/2014 10:13:30 AM
GRAND FORKS, N.D.--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has acquired the rights, in four separate transactions, to three well-studied Candida vaccine antigens, significantly bolstering the Company’s Candida vaccine pipeline. These three antigens are in addition to the Company’s agglutinin-like sequence 3 (Als3) antigen used in NDV-3, NovaDigm’s lead vaccine being evaluated in an on-going Phase 1b/2a study.1 NovaDigm now has four of the five most widely studied Candida antigens, and two of those have successfully completed Phase 1 studies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by